A retrospective on the failures and successes of antibacterial drug discovery

IDrugs

Volumn 8, Issue 8, 2005, Pages 651-655

  Silver, Lynn L ^a  

^a LL Silver Consulting LLC   (United States)

Author keywords

Antibacterial discovery; Antibacterial drugs; Bacterial cell; Natural products; Novel antibacterial agents

Indexed keywords

9 ACETYLIMINO 3 DEHEXAPYRANOSYLOXY 9 DEOXO 3 OXO 6 O,11 O [2 [6 (1 PYRAZOLYL) 3 PYRIDINYLMETHOXYIMINO]PROPYLENE]ERYTHROMYCIN; ACTINONIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; API 1401; BACTERIAL ENZYME; BENZIMIDAZOLE DERIVATIVE; BETA LACTAMASE INHIBITOR; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; ENZYME INHIBITOR; FROPENEM; HYDROXAMIC ACID; ICLAPRIM; KETOLIDE; LINEZOLID; MBX 500; OXAZOLIDINONE DERIVATIVE; PEPTIDE DEFORMYLASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; REP 8839; RIFAMYCIN; TAK 599; TAZOSYN; TELITHROMYCIN; TETRACYCLINE; TIGECYCLINE; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 692;

ANTIBACTERIAL ACTIVITY; BACTERIAL CELL; BIOTECHNOLOGY; CLINICAL TRIAL; DRUG INDUSTRY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; RETROSPECTIVE STUDY; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; HISTORY, 20TH CENTURY; HUMANS; PHARMACOLOGY;

EID: 23244458270     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (7)

1. Bellon S, Parsons JD, Wei Y, Hayakawa K, Swenson LL, Charifson PS, Lippke JA, Aldape R, Gross CH: Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): A single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase. Antimicrob Agents Chemother (2004) 48(5):1856-1864.
2. Bush K, Macielag M, Weidner-Wells M: Taking inventory: Antibacterial agents currently at or beyond phase I. Curr Opin Microbiol (2004) 7(5):466-476.
3. Dougherty TJ, Projan SJ (Eds): Microbial Genomics and Drug Discovery. Marcel Dekker, New York, NY, USA (2003).
4. Gadebusch HH, Stapley EO, Zimmerman SB: The discovery of cell wall active antibacterial antibiotics. Crit Rev Biotechnol (1992) 12(3):225-243.
5. Hajduk PJ, Huth JR, Fesik SW: Druggability indices for protein targets derived from NMR-based screening data. J Med Chem (2005) 48(7):2518-2525.
6. Silver LL, Bostian KA: Discovery and development of new antibiotics: The problem of antibiotic resistance. Antimicrob Agents Chemother (1993) 37(3):377-383.
7. Strahilevitz J, Hooper DC: Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: Direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob Agents Chemother (2005) 49(5):1949-1956.